Amicus Therapeutics Inc. (NASDAQ:FOLD) at last check was buoying at $10.36 on Friday, January 14, with a rise of 4.54% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $9.91 and 5Y monthly beta was reading 1.21 with its price kept floating in the range of $9.80 and $10.58 on the day. Considering stock’s 52-week price range provides that FOLD hit a high price of $23.72 and saw its price falling to a low level of $8.40 during that period. Over a period of past 1-month, stock came subtracting -4.62% in its value.
With its current market valuation of $2.95 billion, Amicus Therapeutics Inc. is set to declare its quarterly results on Feb 28, 2022 – Mar 04, 2022. Analysts are in estimates of -$0.15 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.77 for 2021 with estimates of that growing to -$0.31 in next year. These estimates are suggesting current year growth of 28.00% for EPS and 59.70% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $84.69 million. They suggested that in the process company could generate revenue of as low as $82.8 million which could climb up to $87.9 million to hit a high. The average estimate is representing an increase of 20.00% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $308.26 million in 2021, which will be 18.20% more from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with 1 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review FOLD stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of 50% Buy. Long term indicators are suggesting an average of 50% Sell for it.
According to ratings assigned by 11 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 3 of them are recommending Amicus Therapeutics Inc. (FOLD) as a Hold, while 8 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the FOLD stock which is currently positioned at 0. It further provides that stock’s current price level is -8.31% away from its 20-day simple moving average and is -7.87% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 44.05 while volatility remained at 13.07% over the past week which changes to 7.51% when measuring it over the past month. Beta is valued at 1.19, while measure of average true range or ATR is currently at 0.80. In predicting price targets of as low as $14.00 and as high as $29.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $17.33. Stock’s current price level is -35.14% above from estimated low price target while it is -179.92% below the estimated high; and even if the FOLD’s share succeeded to reach the median price of $16.00, then the outlook of -54.44% could come to the excitement of the investors.
In comparing Amicus Therapeutics Inc. (FOLD)’s stock with other industry players reveals that stock’s latest price change of 4.54% and that of -57.45% over the past 12 months is in competing position with that of Biogen Inc. (BIIB) which saw its stock price fall by -0.95% in the recent trading and went through a decrease of -15.56% in past 12-month trading. Industry’s another major player Novo Nordisk A/S (NVO) has fall -2.34% down in latest trading session, but over the past year has faced arise of 40.17%, while BioMarin Pharmaceutical Inc. (BMRN) was also up 0.71% however its price remained floating in the green at 8.36% over the same period. Amicus Therapeutics Inc. has a P/E ratio of 0 against that of Biogen Inc.’s 23.16 while Novo Nordisk A/S is showing 32.79 for the same. On the other hand, the S&P 500 Index is down -0.47% in the early deals today while the Dow Jones Industrial was dealinglower at -0.78%.
Having a second look at Amicus Therapeutics Inc. (NASDAQ:FOLD) provides that stock’s average daily trading volume for 3 months was 2.49 million. Number of outstanding shares of the stock stood at 267.46 million.
Subtraction of -14.20% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.